Modified Factor Xa Derivatives Neutralize Inhibitors
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current anticoagulant therapies targeting factor Xa (fXa) lack effective and specific antidotes to reverse over-anticoagulation or restore hemostasis, particularly due to the limited ability of recombinant factor VIIa to neutralize direct fXa inhibitors, which poses a risk of inadequate bleeding control.
Innovation Solution
Development of modified factor Xa protein derivatives with reduced or absent intrinsic procoagulant activity that can bind and neutralize fXa inhibitors, such as by modifying the Gla domain or active site, allowing them to act as antidotes without assembling into the prothrombinase complex.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If recombinant factor VIIa is used to reverse fXa inhibitors, then some neutralization effect is achieved, but the antidote activity is insufficient and bleeding control is inadequate
Solution Approach 1:
The patent extracts the inhibitor-binding capability from functional factor Xa by creating a derivative that lacks procoagulant activity. This is achieved by removing or modifying the Gla domain (residues 1-45) and/or the active site (residues 195-448), resulting in a factor Xa derivative that can bind inhibitors but cannot activate prothrombin, thus providing pure antidote activity without procoagulant side effects
Solution Approach 2:
Instead of using active factor Xa or factor VIIa to reverse inhibition, the patent inverts the approach by using an inactive derivative that binds the inhibitor without exerting procoagulant activity. The derivative is designed to have high affinity for the inhibitor while lacking the catalytic function, effectively reversing the inhibition through binding alone
2Object-affected harmful factors
If factor Xa inhibitors are administered to prevent thrombosis, then thrombus formation is reduced, but over-anticoagulation and bleeding risk increase
Solution Approach 1:
The factor Xa derivative acts as an intermediary substance that mediates between the inhibitor and the coagulation system. It binds to the inhibitor with high affinity, preventing the inhibitor from blocking factor Xa, while the derivative itself remains inactive and does not trigger excessive coagulation, thus mediating the reversal without causing harm
3Reliability
If specific antidotes are developed for fXa inhibitors, then reversal efficacy is improved, but device complexity and development challenges increase
Solution Approach 1:
The factor Xa derivative serves multiple functions: it binds to direct fXa inhibitors (such as rivaroxaban, apixaban, betrixaban), provides reversal of anticoagulation, and does so through a single molecular mechanism. This multi-functionality simplifies the development process compared to creating separate antidotes for different inhibitor types, as the same derivative structure works across multiple applications
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These derivatives effectively neutralize fXa inhibitors, preventing or reducing bleeding by selectively binding and inhibiting exogenously administered fXa inhibitors, thereby restoring normal hemostasis without causing thrombosis, as demonstrated by their ability to reverse anticoagulant activity in clinical scenarios.
Implementation Method 1
modified factor Xa protein derivatives with reduced or absent intrinsic procoagulant activity that can bind and neutralize fXa inhibitors
Data Source
AI summary
The present invention relates antidotes to anticoagulants targeting factor Xa. The antidoes are factor Xa protein derivatives that bind to the factor Xa inhibitors thereby substantially neutralizing them but do not assemble into the prothrombinase complex. The derivatives describe herein lack or have reduced intrinsic coagulant activity. Disclosed herein are methods of stopping or preventing bleeding in a patient that is currently undergoing anticoagulant therapy with a factor Xa inhibitor.